ROS1 mutation
Updates to Article Attributes
Body
was changed:
The ROS 1 mutation is a mutation occurring in the ROS 1 oncogene in chromosome 6 resulting in a defective a receptor tyrosine kinase which has structural similarity to the anaplastic lymphoma kinase (ALK) protein.
It is thought be present in several cancers inclusive non-small cell lung cancers (NSCLC) occur in 1(1-2 % of the latter NSCLC).
Clinical imporantance
Useful for assessing appropriateness of treatment agents such as Crizotinib
History and etymology
It is thought to have been first identified by Rikova et al 3
See also
-<p>The <strong>ROS 1 mutation</strong> is a mutation occurring in the ROS 1 oncogene resulting in defective a receptor tyrosine kinase which has structural similarity to the anaplastic lymphoma kinase (ALK) protein.</p><p>It is thought be present in several cancers inclusive of glioblastoma and <a title="non-small cell lung cancers" href="/articles/non-small-cell-lung-cancers">non-small cell lung cancers</a> (NSCLC) occur in 1-2 % of the latter.</p><h4>Clinical imporantance</h4><p>Useful for assessing appropriateness of treatment agents such as Crizotinib </p><h4>History and etymology</h4><p>It is thought to have been first identified by <strong>Rikova</strong> et al <sup>3</sup></p><h4><strong>See also</strong></h4><ul>-<li><a title="EGFR mutation" href="/articles/egfr-mutation">EGFR mutation</a></li>-<li><a title="KRAS mutation" href="/articles/kras-mutation">KRAS mutation</a></li>-<li><a title="Anaplastic lymphoma kinase (ALK) gene rearrangements" href="/articles/anaplastic-lymphoma-kinase-alk-gene-rearrangements">anaplastic lymphoma kinase (ALK) gene rearrangements</a></li>- +<p>The <strong>ROS 1 mutation</strong> is a mutation occurring in the ROS 1 oncogene in chromosome 6 resulting in a defective receptor tyrosine kinase which has structural similarity to the anaplastic lymphoma kinase (ALK) protein.</p><p>It is thought be present in several cancers inclusive <a href="/articles/non-small-cell-lung-cancers">non-small cell lung cancers</a> (NSCLC) (1-2 % of NSCLC).</p><h4>Clinical imporantance</h4><p>Useful for assessing appropriateness of treatment agents such as Crizotinib</p><h4>History and etymology</h4><p>It is thought to have been first identified by <strong>Rikova</strong> et al <sup>3</sup></p><h4>See also</h4><ul>
- +<li><a href="/articles/egfr-mutation">EGFR mutation</a></li>
- +<li><a href="/articles/kras-mutation">KRAS mutation</a></li>
- +<li><a href="/articles/anaplastic-lymphoma-kinase-alk-gene-rearrangements">anaplastic lymphoma kinase (ALK) gene rearrangements</a></li>
- +<li><a href="/articles/her-2-mutations-in-lung-cancer">HER-2 mutations in lung cancer</a></li>
References changed:
- 1. Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. (2017) Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 12 (11): 1611-1625. <a href="https://doi.org/10.1016/j.jtho.2017.08.002">doi:10.1016/j.jtho.2017.08.002</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28818606">Pubmed</a> <span class="ref_v4"></span>
- 2. Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. (2016) Virchows Archiv : an international journal of pathology. 469 (5): 489-503. <a href="https://doi.org/10.1007/s00428-016-2000-3">doi:10.1007/s00428-016-2000-3</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/27535289">Pubmed</a> <span class="ref_v4"></span>
- 3. Joshi A, Pande N, Noronha V, Patil V, Kumar R, Chougule A, Trivedi V, Janu A, Mahajan A, Prabhash K. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. (2019) Ecancermedicalscience. 13: 900. <a href="https://doi.org/10.3332/ecancer.2019.900">doi:10.3332/ecancer.2019.900</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/30915158">Pubmed</a> <span class="ref_v4"></span>
Systems changed:
- Chest
Unable to process the form. Check for errors and try again.